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Pharmacological therapy of back pain with analgesics and anti-inﬂammatory drugs is frequently associated with adverse eﬀects,
particularly in the elderly. Aim of this study was to compare mesotherapic versus conventional systemic administration of
nonsteroidal anti-inﬂammatory drugs (NSAIDs) and corticosteroids in patients with acute low back pain. Eighty-four patients
were randomized to receive anti-inﬂammatory therapy according to the following protocols: (a) mesotherapy group received the
1st and 4th day 2% lidocaine (1mL) + ketoprofen 160mg (1mL) + methylprednisolone 40mg (1mL), then on 7th, 10th, and
13th day, 2% lidocaine (1mL) + ketoprofen 160mg (1mL) + methylprednisolone 20mg (1mL) (b) conventional therapy group
received ketoprofen 80mg × 2/die and esomeprazole 20mg/die orally for 12 days, methylprednisolone 40mg/die intramuscularly
for 4 days, followed by methylprednisolone 20mg/die for 3 days, and thereafter, methylprednisolone 20mg/die at alternate days.
Pain intensity and functional disability were assessed at baseline (T0), at the end of treatment (T1), and 6 months thereafter (T2)
by using visual analogic scale (VAS) and Roland-Morris disability questionnaire (RMDQ). In both groups, VAS and RMDQ values
were signiﬁcantly reduced at the end of drug treatment and after 6 months, in comparison with baseline. No signiﬁcant diﬀerences
were found between the two groups. This suggests that mesotherapy may be a valid alternative to conventional therapy in the
treatment of acute low back pain with corticosteroids and NSAIDs.
1.Introduction
Low back pain aﬀects a high proportion of adult popula-
tion in the developed countries and has a major impact
on health care system and society [1, 2]. Conventional
pharmacological therapy to reduce pain, inﬂammation,
and functional disability usually relies upon the extensive
use of nonsteroidal anti-inﬂammatory drugs (NSAIDs),
paracetamol (acetaminophen), corticosteroids, and various
opioids. However, the major drawback of pharmacological
therapy with analgesics and anti-inﬂammatory drugs is the
frequent association with adverse eﬀects [3]; in particular,
NSAID-related toxicity is connected to the inhibition of con-
stitutive prostaglandins (PGs), with consequent impairment
of gastric mucosal defense and renal homeostasis [4]. On
the other hand, the availability of selective cyclooxygenase-2
(COX-2) inhibitors (Coxibs), despite providing a reduction
in the gastrointestinal toxicity, resulted in a high risk of
developing serious cardiovascular and renal side eﬀects
[5, 6]. Chronic therapy with systemic corticosteroids may
aﬀord a variety of serious untoward reactions, leading to
hypertension,diabetes,glaucoma,gastriculcer,osteoporosis,
and psychiatric disorders [7, 8]. Finally, opioids, used either
alone or in combination with paracetamol and/or NSAIDs,
may cause a variety of side eﬀects which are dose-limiting
and reduce quality of life, bowel dysfunction being one of
the most common and persisting problems [9]. Thus, new
therapeutic options endowed with comparable eﬃcacy and
better safety are warranted.
Among the various attempts to reduce drug toxicity,
the use of local therapy (neural block, intraarticular, or
periarticular injections of corticosteroids) has gained popu-
larity among physicians [10, 11] ,d e s p i t es o m ec o n t r o v e r s i e s
concerning its eﬃcacy as a therapeutic remedy [12].2 Evidence-Based Complementary and Alternative Medicine
Mesotherapy Systemic therapy
1 cc lidocaine 2% added to injections
84 patients
randomized
N = 42 N = 42
Ketoprofen 160mg + methylprednisolone
40mg at day 1 and 4;
Esomeprazole 20mg/die for 12days
Ketoprofen 80mg ×2/die orally for 12days
Methylprednisolone 40mg/die i.m. for the
ﬁrst 4days
Ketoprofen 160mg + methylprednisolone
20mg at day 7, 10, and 13
Methylprednisolone 20mg/die i.m. at day
5, 6, and 7
Methylprednisolone 20mg/die i.m. at day
8, 10, and 12
Figure 1: Study design and drug treatment.
During the last decades, researchers and patients have
become increasingly interested in complementary and alter-
native medicine (CAM) as a possible mean to ensure eﬃcacy,
while improving therapeutic safety [13–15]. Back pain,
in particular, is the most common reason for CAM use
both in Europe and USA [15]. However, despite the large
favour by the general population and several published
clinical studies, only few physical treatments are supported
by strong scientiﬁc evidence [16–18]; likewise, controlled
clinical studies evaluating the eﬀectiveness of the most
popularCAMtherapiesusedforlowbackpainarestillscarce
[19], very few mechanistic studies are available [20, 21], the
quality of research is generally poor, and general conclusions
are diﬃcult to reach [16].
Mesotherapy was introduced 50 years ago by Michel
Pistor, a French physician who utilized this technique as
a novel analgesic therapy for a variety of rheumatologic
disorders [22]. Mesotherapy is a minimally invasive tech-
nique that consists of subcutaneous injections of drugs and,
occasionally, plant extracts, homeopathic agents, or other
bioactive substances; for this reason, it has been often con-
sidered a CAM, rather than a conventional medical therapy
[23, 24]. Since its introduction, the use of mesotherapy has
been expanded, and therapeutic indications have increased;
although most applications are found in osteoarticular
pathologies [25–28], over the recent years, this technique has
become popular in cosmetic medicine for the treatment of
cellulite and fat deposition [29, 30].
Based on these premises, the following study was
designed to evaluate the eﬀectiveness of anti-inﬂammatory
drugs (NSAIDs and corticosteroids) administered via
mesotherapy in comparison with conventional systemic
therapy by oral and intramuscular route, for the treatment
of acute low back pain.
2. Methods
The study was carried out at the Department of Physical
Medicine and Rehabilitation of the University of Parma
following the guidelines for experimental investigation with
human subjects required by the local University. Informed
written consent was obtained from each patient.
2.1. Patient Recruitment. Patients were recruited for the
study from the Emergency Department between January
and May 2007 and checked for eligibility by the clinical
investigator. Patients were enrolled into the study, provided
that they had been suﬀering from back pain since no more
than 2 weeks and reported a current pain intensity >65
on a 100mm visual analogic scale (VAS). Exclusion criteria
were represented by diabetes, anticoagulant therapy, or
pregnancy.Patientswerealsoexcludediftheyhadevidenceof
cardiovascular, renal, hepatic, gastrointestinal, or psychiatric
diseases. Eighty-four patients (44 men, 40 women) aged
24–77 years and suﬀering from acute low back pain, with
cruralgia or sciatalgia were included into the study. Patients
could leave the study at any time for any reason.
2.2. Study Design. Patients who met the eligibility criteria
were randomly allocated to receive anti-inﬂammatory ther-
apy with NSAIDs (ketoprofen) and corticosteroids (methyl-
prednisolone, MP), administered either by mesotherapic
technique or by oral/intramuscular route, according to the
study plan described in Figure 1.
DrugregimenemployedingroupA(22men,20women)
was as follows: 2% lidocaine (1mL) + ketoprofen 160mg
(1mL) + MP 40mg (1mL) at day 1 and 4, then 2% lidocaine
(1mL) + ketoprofen 160mg (1mL) + MP 20mg (1mL) at
day 7, 10, and 13. Five repeated injections (3mL for eachEvidence-Based Complementary and Alternative Medicine 3
Figure 2:Injection pointsofasinglemesotherapictreatment.Drug
injections were administered along the running of sciatic nerve,
through speciﬁc needles (30G × 4mm) (see Methods, for details).
injection) were administered at inter and paravertebral level
along the running of sciatic nerve, through speciﬁc needles
(30G × 4mm), which were inserted deeply for the whole
lenght (Figure 2). Lidocaine was used to minimize pain at
site of injection.
G r o u pB( 2 2m e n ,2 0w o m e n )r e c e i v e dd r u gt h e r a p y
accordingtothefollowingprotocol:ketoprofen80mgX2/die
orally for 12 days; MP intramuscularly 40mg/die for the ﬁrst
4 days, then 20mg/die for 3 days, then 20mg/die at alternate
days. Patients of this group received esomeprazole 20mg/die
for 12 days, as gastroprotective therapy.
2.3. Outcome Measures. Self-rated pain intensity was
assessed by using the VAS scale (0 = no pain, 100 intolerable
pain),ahorizontal, unmarked 100mmscalewidelyvalidated
to assess pain [31]. Functional disability in the daily life
activity was measured by the Roland-Morris disability
questionnaire (RMDQ) (varying score from 0 to 24). Both
parameters were evaluated at baseline (T0), at the end of the
drug treatment (12 days, T1), and at 6 months thereafter
(follow up, T2) by two independent observers blind to the
pharmacological treatment.
2.4. Statistical Analysis. All quantitative data were entered
into a speciﬁcally designed database (SPSS V 17.01). Chi-
Square Mann-Whitney and Kolmogorov-Smirnov test were
employedtoevaluatetheomogeneityofthegroups,asforsex
or age, respectively. Wilcoxon signed rank test was utilized
to analyze the variations among values obtained at baseline
(T0), end of treatment (T1), followup (T2), and T0-T1, T1-
T2; Krusall-Wallis test was used to analyze diﬀerences among














Figure 3: Eﬀect of anti-inﬂammatory drugs on the reduction
of pain, as measured by visual analogic scale (VAS) in patients
with acute low back pain. Drug treatment was done either via
mesotherapy or via standard systemic route of administration (see
methods for details). T0 = baseline, T1 = end of the 12-day
treatment and T2 = six months after the end of drug treatment.
















Figure 4: Eﬀect of anti-inﬂammatory drugs on the reduction
of functional disability, as measured by Roland-Morris disability
questionnaire (RMDQ), in patients with acute low back pain.
Drug treatment was done either via mesotherapy or via standard
systemic route of administration. T0 = baseline, T1 = end of 12-day
treatment, and T2 = six months after the end of drug treatment.
Values are mean ± SD from 42 patients.
test for independent data. A P value <. 05 was considered
statistically signiﬁcant.
3. Results
3.1. Patient Characteristics. A total of 84 patients were
enrolled into the study. All treated groups were balanced4 Evidence-Based Complementary and Alternative Medicine
Table 1: Baseline characteristics of patients.
Mesotherapy Conventional systemic therapy P Test
Males, no. 22 22 .827 χ2
Females, no. 20 20 .827 χ2
Age, mean (SD), y 53.5 (2.64) 53.0 (2.7) .895 Kolmogorov-Smirnov
VAS, mean (SD) 86.5 (13.22) 80.5 (5.12) .554 Mann-Whitney
RMDQ, mean (SD) 17 (13.76) 16.5 (14.56) .613 Mann-Whitney














Figure 5: Therapeutic outcome of mesotherapy in comparison with conventional systemic therapy for acute low back pain. These two
routes of administration resulted in comparable eﬃcacy, despite the lower (approximately 50%) total amount of drug administered via
mesotherapy.
with respect to demographic and baseline characteristics
(Table 1). In particular, the patient distribution between the
groups was comparable as for sex and age, scores for pain
(VAS), and functional disability (RMDQ).
3.2. Pain and Functional Disability. In group A (mesother-
apy),VASandRMDQscoresweresigniﬁcantlyreducedatthe
end of the pharmacological treatment (P<.0001) whereas
after 6 months only VAS score was still signiﬁcantly diﬀerent
from baseline (P = .04) (Figure 3). In group B (conven-
tional pharmacotherapy),VAS and RMDQ were signiﬁcantly
reducedattheendofthetreatment(P<.0001andP<.001,
resp.) and both scores were still signiﬁcantly diﬀerent from
baseline after 6 months (P =.673 and P =.400, resp., versus
dataattheendofdrugadministration)(Figure4).Mesother-
apy was well-tolerated and local or allergic reactions were
not observed. Minimal pain during and after injection was
prevented by the local anaesthetic. Transient bleeding and
signs of inﬂammation occurred in patients at the site of
injection, but they resolved in a few days.
4. Discussion
The aim of this study was to evaluate the eﬀectiveness of
anti-inﬂammatory drugs administered via mesotherapy in
patients with acute low back pain. Present results showed
for the ﬁrst time that the administration of NSAIDs and
corticosteroids via mesotherapic technique can provide the
same therapeutic beneﬁt as that induced by conventional
(oral and intramuscular) drug administration. Indeed, both
treatments signiﬁcantly reduced pain intensity and disability
in daily life activity, and the eﬀect was maintained up to
6 months. These results are in accordance with previous
studies showing that naproxen and diclofenac, administered
via mesotherapy, were more eﬀective than after oral admin-
istration [27, 32, 33].
The major ﬁnding of this study is the comparable
eﬀectiveness of mesotherapy and conventional systemic
therapy, despite the lower amount of drugs administered
to patients undergoing mesotherapy (41,67% ketoprofen
and 50% methylprednisolone) (Figure 5). The comparable
eﬃcacy of mesotherapy and conventional therapy, despite
diﬀerent drug dosages, is diﬃcult to explain. Subcutaneous
drug administration results in a very slow drug absorption
in comparison with other systemic routes, such as oral
and intramuscular; thus it could be hypothesized that anti-
inﬂammatory drugs, administered via mesotherapy, achieve
a high drug concentration into the subcutaneous tissue
and exert local eﬀects in close proximity to inﬂammatory
cells, sensory ﬁbers, and vascular mediators that orchestrate
inﬂammation and pain.Evidence-Based Complementary and Alternative Medicine 5
Although no measurement was made in our study of
drug plasma levels after the two routes of administration,
it is presumable to hypothesize that mesotherapic treatment
resulted in a lower systemic bioavailability of drugs, with
consequent lower incidence of adverse reactions. This could
oﬀer a great therapeutic advantage, when considering the
high rates of adverse eﬀects, associated with NSAID or
corticosteroid use in the elderly population [3, 4, 7]. While
the use of proton pump inhibitors has signiﬁcantly limited
the incidence of peptic ulceration and other acid-related dis-
orders[34],renalandcardiovascularproblemsstillremainof
particularconcern.Inthisconnection,bothnonselectiveand
COX-2-selective NSAIDs were found to reduce glomerular
ﬁltration, increase ﬂuid retention and blood pressure [5, 6],
and some highly selective COX-2 inhibitors were found
unfavourable in patients with cardiovascular diseases and
were withdrawn from the market [5, 35]. Corticosteroids, on
the other hand, may have a variety of side eﬀects, including
hypertension, diabetes, osteoporosis, glaucoma, and peptic
ulcer, which are dose-dependent and related to the systemic
drug availability [7, 8].
Although mesotherapic techniques used in dermatologic
surgery have been associated with a number of adverse
eﬀects at sites of injection, including atypical mycobacterial
infections [36], urticaria [37], lichenoid drug eruptions [38,
39], and psoriasis [40], no evidence of local reactions were
found in the present study.
Inconclusion,resultsofthestudyindicatethatcombined
administration of conventional NSAIDs and corticosteroids
by mesotherapy is an eﬀective and well-tolerated method for
managing low back pain in the short-term, compared with
drug therapy administered by oral and intramuscular route.
Possible weaknesses of our study are the small number of
patients, the short followup period, and the lack of drug
plasma level measurements. However, if conﬁrmed in a large
trial, these observations could be of potential interest in
the pharmacological treatment of low back pain to reduce
the adverse eﬀects associated with high plasma levels of
antiinﬂammatory drugs.
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